5-Alpha-reductase inhibitors in diseases of the prostate.
Boston, United States. In Curr Opin Endocrinol Diabetes Obes, 2014
PURPOSE OF REVIEW: To summarize the history of the use of 5-alpha-reductase inhibitors in the treatment of urologic diseases and discuss the current practices and indications for therapy.
Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.
Birmingham, United Kingdom. In J Clin Endocrinol Metab, 2009
MAIN OUTCOME MEASURES: We measured urinary steroid metabolites including glucocorticoids and androgens and the ratios reflecting enzymatic activities involved in peripheral cortisol and androgen metabolism, 5 alpha-reductase, and 11 beta-hydroxysteroid dehydrogenase types 1 and 2. We also measured circulating levels of glucose, insulin, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone and calculated homeostasis model assessment.
Diagnosis of 5alpha-reductase 2 deficiency: a local experience.
Hong Kong, Hong Kong. In Hong Kong Med J, 2009
5Alpha-reductase 2 deficiency is an autosomal recessive disorder characterised by lack of masculinisation in XY individuals due to failure to convert testosterone to dihydrotestosterone, the bioactive androgen.
46,XY DSD with Female or Ambiguous External Genitalia at Birth due to Androgen Insensitivity Syndrome, 5alpha-Reductase-2 Deficiency, or 17beta-Hydroxysteroid Dehydrogenase Deficiency: A Review of Quality of Life Outcomes.
Oklahoma City, United States. In Int J Pediatr Endocrinol, 2008
The current review focuses on information published since 1955 pertaining to psychological well-being, cognition, general health, fertility, and sexual function in people affected by androgen insensitivity syndromes, 5-alpha reductase-2 deficiency, or 17beta-hydroxysteroid dehydrogenase-3 deficiency-reared male or female.